Literature DB >> 24220556

Transcription factor STAT3 as a prognostic marker and therapeutic target in cancer.

David A Frank1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24220556     DOI： 10.1200/JCO.2013.52.8414

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Benzyl Isothiocyanate (BITC) Induces Reactive Oxygen Species-dependent Repression of STAT3 Protein by Down-regulation of Specificity Proteins in Pancreatic Cancer.

Authors:  Ravi Kasiappan; Indira Jutooru; Keshav Karki; Erik Hedrick; Stephen Safe
Journal:  J Biol Chem       Date:  2016-11-15       Impact factor: 5.157

2.  Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.

Authors:  Michael Xiang; Haesook Kim; Vincent T Ho; Sarah R Walker; Michal Bar-Natan; Melodi Anahtar; Suhu Liu; Patricia A Toniolo; Yasmin Kroll; Nichole Jones; Zachary T Giaccone; Lisa N Heppler; Darwin Q Ye; Jason J Marineau; Daniel Shaw; James E Bradner; Traci Blonquist; Donna Neuberg; Claudio Hetz; Richard M Stone; Robert J Soiffer; David A Frank
Journal:  Blood       Date:  2016-08-16       Impact factor: 22.113

3.  A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions.

Authors:  Nicole Alonso; Roboan Guillen; Jeremy W Chambers; Fenfei Leng
Journal:  Nucleic Acids Res       Date:  2015-02-04       Impact factor: 16.971

4.  Antiproliferative pharmacophore azo-hydrazone analogue BT-1F exerts death signalling pathway targeting STAT3 in solid tumour.

Authors:  Ankith Sherapura; Vikas H Malojirao; B S Sharath; Prabhu Thirusangu; Riaz Mahmood; N Suchetha Kumari; Shrinath M Baliga; Shaukath Ara Khanum; B T Prabhakar
Journal:  Pharmacol Rep       Date:  2022-01-10       Impact factor: 3.024

5.  Dysregulated transcription across diverse cancer types reveals the importance of RNA-binding protein in carcinogenesis.

Authors:  Jing Wang; Qi Liu; Yu Shyr
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

6.  ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer.

Authors:  Min Ho Choe; Joong Won Min; Hong Bae Jeon; Dong-Hyung Cho; Jeong Su Oh; Hyun Gyu Lee; Sang-Gu Hwang; Sungkwan An; Young-Hoon Han; Jae-Sung Kim
Journal:  Oncotarget       Date:  2015-02-20

7.  STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.

Authors:  Jae-Sung Kim; Hyun-Ah Kim; Min-Ki Seong; Hyesil Seol; Jeong Su Oh; Eun-Kyu Kim; Jong Wook Chang; Sang-Gu Hwang; Woo Chul Noh
Journal:  Oncotarget       Date:  2016-02-09

8.  B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

Authors:  Xingli Zhao; Zhuoran Zhang; Dayson Moreira; Yu-Lin Su; Haejung Won; Tomasz Adamus; Zhenyuan Dong; Yong Liang; Hongwei H Yin; Piotr Swiderski; Raju K Pillai; Larry Kwak; Stephen Forman; Marcin Kortylewski
Journal:  Mol Ther       Date:  2018-01-17       Impact factor: 11.454

Review 9.  Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.

Authors:  Samia S Messeha; Najla O Zarmouh; Karam F A Soliman
Journal:  Nutrients       Date:  2021-05-19       Impact factor: 5.717

10.  Functional consequence of the p53 codon 72 polymorphism in colorectal cancer.

Authors:  Venkat R Katkoori; Upender Manne; Lakshmi S Chaturvedi; Marc D Basson; Pam Haan; Daniel Coffey; Harvey L Bumpers
Journal:  Oncotarget       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.